Group 1 - The company Yongtai Bio-B (06978) announced that all conditions precedent under the subscription agreement have been met or waived, if applicable [1] - The company has issued new convertible bonds with a total principal amount of RMB 270 million and notes with a principal amount of RMB 30 million to investors according to the terms and conditions [1] - The proceeds from the subscription will be used exclusively for the full and final repayment of the principal amount of the 2023 convertible bonds, which are due on February 20, 2026 [1]

Core Viewpoint - Yongtai Bio-B (06978.HK) has announced a conditional agreement to issue new convertible bonds and notes, aimed at repaying existing convertible bonds due in February 2026 [1] Group 1: Financial Details - The company will issue new convertible bonds amounting to RMB 270 million, with an initial conversion price of HKD 2.92 per share [1] - Additionally, the company will issue notes amounting to RMB 30 million [1] - The proceeds from the issuance will be used exclusively for the full repayment of the 2023 convertible bonds maturing on February 20, 2026 [1] Group 2: Share Issuance Impact - Upon full exercise of the conversion rights attached to the new convertible bonds, a maximum of 102,880,787 shares will be issued, representing approximately 16.66% of the existing issued shares and about 14.28% of the enlarged issued shares post-issuance [1] Group 3: Conditions and Agreements - The issuance of the new convertible bonds and notes is contingent upon the company paying the accrued unpaid interest on the 2023 convertible bonds and fulfilling other specified conditions [1] - Investors are required to sign a repayment deed benefiting the company, confirming the full and final repayment of the 2023 convertible bonds upon receipt of the new bonds and notes [1]

Group 1 - The company Yongtai Biological-B (06978) issued convertible bonds on February 20, 2023, which will mature on February 20, 2026 [1] - A framework agreement was established with investor Jiaze Global Capital Limited, the existing holder of the 2023 convertible bonds, for the subscription of new convertible bonds worth 270 million HKD and notes worth 30 million HKD [1] - The proceeds from the subscription will be used exclusively for the full and final repayment of the principal amount of the 2023 convertible bonds [1] Group 2 - The initial conversion price of the new convertible bonds is set at 2.92 HKD per share, which represents a premium of approximately 5.8% over the last trading price of 2.76 HKD per share on the Hong Kong Stock Exchange [1]

Core Viewpoint - Yongtai Bio-B (06978) has issued convertible bonds in 2023, with a framework agreement established for new bond subscriptions to repay existing bonds [1] Group 1: Bond Issuance Details - The 2023 convertible bonds were issued on February 20, 2023, and will mature on February 20, 2026 [1] - A framework agreement was signed with investor Jiaze Global Capital Limited on January 20, 2026, for the subscription of new convertible bonds worth 270 million HKD and notes worth 30 million HKD [1] - The proceeds from the subscription will be used exclusively for the full repayment of the principal amount of the 2023 convertible bonds [1] Group 2: Pricing Information - The initial conversion price for the new convertible bonds is set at 2.92 HKD per share, which is approximately 5.8% higher than the last trading price of 2.76 HKD per share on the Hong Kong Stock Exchange [1]